Drugs / VECABRUTINIB
VECABRUTINIB
also known as
BIIB-062 · BSK-4841 · BSK-4841 SUCCINATE · FP-0182 · SNS-062 · SNS-062 succinate · VECABRUTINIB SUCCINATE
Small molecule targets BTK via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03037645 | Apr 2017 → Aug 2020 | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma activated B-cell type, follicular lymphoma +2 | Sunesis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VECABRUTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297640 ↗ |
| Known as | BIIB-062 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297640 ↗ |
| Known as | BSK-4841 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297640 ↗ |
| Known as | BSK-4841 SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297640 ↗ |
| Known as | FP-0182 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297640 ↗ |
| Known as | SNS-062 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03037645 ↗ |
| Known as | SNS-062 succinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297640 ↗ |
| Known as | VECABRUTINIB SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297640 ↗ |
| Action | Inhibit | “A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies” NCT03037645 ↗ |
| Modality | Small molecule | — CHEMBL4297640 ↗ |
| Route | Oral | “SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.” NCT03037645 ↗ |
| Target | BTK | “A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies” NCT03037645 ↗ |